In which clinical situations is Jardiance (empagliflozin) contraindicated?

Absolute Contraindications for Jardiance (Empagliflozin)

Jardiance is contraindicated in only three specific situations: (1) known hypersensitivity to empagliflozin or any excipients, (2) patients on dialysis, and (3) severe renal impairment with eGFR <30 mL/min/1.73 m² in patients without established cardiovascular disease or cardiovascular risk factors. 111

Absolute Contraindications

1. Hypersensitivity Reactions

• Any history of serious hypersensitivity to empagliflozin or tablet excipients (including angioedema)
• If hypersensitivity occurs during treatment, discontinue immediately and treat per standard protocols 11

2. Dialysis

• Jardiance is absolutely contraindicated in patients requiring dialysis
• Studies did not enroll patients with eGFR <20 mL/min/1.73 m², and removal by hemodialysis has not been studied 1

3. Severe Renal Impairment (Context-Dependent)

• For glycemic control only: Do not use when eGFR <30 mL/min/1.73 m² in patients without established cardiovascular disease or cardiovascular risk factors
• Important exception: Patients with established cardiovascular disease or heart failure may continue Jardiance for cardiovascular and kidney benefits even with eGFR as low as 20 mL/min/1.73 m² until dialysis or transplantation 21

Critical Clinical Situations Requiring Caution (Not Absolute Contraindications)

While not contraindications, these situations require careful assessment and may necessitate temporary discontinuation:

Volume Depletion States

• Assess before initiating in patients with eGFR <60 mL/min/1.73 m², elderly patients (especially >75 years), or those on loop diuretics
• Correct volume depletion before starting Jardiance
• Higher risk in elderly: volume depletion events occurred in 4.4% of patients ≥75 years on 25 mg dose versus 2.1% on placebo 11

Perioperative Management

• Discontinue 3-4 days before scheduled surgery to reduce diabetic ketoacidosis (DKA) risk
• Also discontinue during critical illness or prolonged fasting 2

Active Serious Infections

• Evaluate and treat urinary tract infections (including urosepsis/pyelonephritis) promptly before continuing
• If Fournier's gangrene suspected (genital/perineal pain, erythema, swelling with fever), discontinue immediately, start broad-spectrum antibiotics, and perform surgical debridement if needed 11

Key Dosing Considerations by Renal Function

The 2025 ADA guidelines clarify that glucose-lowering efficacy diminishes at eGFR <45 mL/min/1.73 m², but cardiovascular and kidney benefits persist, so continue until dialysis or transplantation 2:

• eGFR ≥45 mL/min/1.73 m²: Full glycemic and cardiovascular benefit
• eGFR 30-44 mL/min/1.73 m²: Minimal glucose-lowering effect but maintain for cardiovascular/kidney protection in appropriate patients
• eGFR 20-29 mL/min/1.73 m²: Insufficient data for dosing recommendation; use only in established cardiovascular disease/heart failure
• eGFR <20 mL/min/1.73 m² or dialysis: Contraindicated

Common Pitfalls to Avoid

1. Don't confuse relative cautions with absolute contraindications: Metformin is contraindicated at eGFR <30; Jardiance has more nuanced renal dosing based on indication 2

2. Don't withhold in heart failure patients with low eGFR: The cardiovascular benefits extend to eGFR as low as 20 mL/min/1.73 m² in appropriate patients 1

3. Don't forget sick-day planning: Educate patients to hold during acute illness, dehydration, or before surgery to prevent rare but serious DKA 2

4. Age alone is not a contraindication: While elderly patients (>75 years) have higher rates of volume depletion and UTIs, careful monitoring allows safe use 1